AC Immune (@AC_Immune_SA) / Twitter
Early data from AC Immune Alzheimer's vaccine suggests response
Parkinson's Disease: AC Immune Receives a Grant from The Michael J. Fox Foundation - BioAlps
NOVEL THERAPEUTICS AND DIAGNOSTICS FOR ALZHEIMER'S AND OTHER NEURODEGENERATIVE DISEASES
Morphomer® and SupraAntigen® | AC Immune's Technology Platforms
AC Immune (@AC_Immune_SA) / Twitter
ACI-7104 / AC Immune
AC Immune's Robust Pipeline focused on neurodegenerative diseases
New Vaccine Formulation Shows Promise for Alzheimer's Target | BioSpace
AC Immune - AnnualReports.com
AC Immune show first images from alpha-synuclein PET
AC Immune and Roche rocked by Alzheimer's failure
AC Immune Gets €28M from Eli Lilly as Alzheimer's Drug Hits Phase I
AC Immune picks up Phase 2-ready drug for Parkinson's in $58M deal with Affiris - MedCity News
AC Immune: Dementia-Focused Swiss Biotech With A Sad History Of Failures (NASDAQ:ACIU) | Seeking Alpha
AC Immune (@AC_Immune_SA) / Twitter
A Full Position In AC Immune To My Tax Loss Selling Basket (ACIU) | Seeking Alpha
Genentech, AC Immune reveal more about crenezumab failure
AC Immune – Swiss Biotech
AC Immune (@AC_Immune_SA) / Twitter
AC Immune logo in transparent PNG format
AC Immune (@AC_Immune_SA) / Twitter
AC Immune acquires Parkinson's vaccine candidate
AC Immune on Twitter: "Register today to join the live webcast of AC Immune's Key Opinion Leader meeting on treating Alzheimer's in Down syndrome at 8am ET, 11 July 2019. https://t.co/7E06v5ew2s #Downsyndrome #
Who is AC Immune? A cutting-edge company with a robust pipeline
Treatments & preventive strategies for neurodegenerative diseases
AC Immune and J&J Advance Tau-Targeting Alzheimer's Vaccine :: Scrip
